The recurrences of cervical cancer: Possibilities of molecular prediction

The incidence of recurrence of cervical cancer ranges from 10 to 40 %. The 5-year survival rate for patients with recurrent cervical cancer is about 5–15 % against the background of current drug therapy. Clinical and morphological characteristics of the tumor process are known, which are used as markers of an unfavorable prognosis for the development of cervical cancer recurrence. The search for molecular prognostic markers of the course of cervical cancer continues.

The aim. To determine the level of immune cycle proteins in patients with cervical cancer 0–IV stages, depending on the occurrence of a relapse of the disease.

Materials and research methods. A retrospective analysis of previously obtained results of a study on the local level of immune cycle proteins in patients with cervical cancer was performed. Three years after follow-up, 2 groups were formed: group 1 – patients treated for cervical cancer without signs of disease progression (n = 83); group 2 – patients with cervical cancer with local or systemic recurrence (n = 18). Used statistical methods: non-parametric methods of statistics using the Kruskal – Wallis test; ROC-analysis for significant values in order to calculate threshold values; determination of the quality of the identified predictive markers by calculating the sensitivity, specificity, accuracy.

Results. Local initial threshold values have a predictive value for predicting the occurrence of cervical cancer recurrence: B7.2 < 10.7 pg/ml (Se = 0.87; Sp = 0.73; Ac = 0.76; AUC = 0.78), PD-L1 ≤ 5.1 pg/ml (Se = 0.87; Sp = 0.68; Ac = 0.71; AUC = 0.76), sCD27 ≥ 32.0 pg/ml (Se = 0.75; Sp = 0.78; Ac = 0.78; AUC = 0.75).

Conclusion. Determination of local levels of B7.2, PD-L1, sCD27 in patients with cervical cancer before treatment can be used to predict the development of disease recurrence during 3 years of follow-up.

1. Kaprin AD, Starinsky VV, Shakhzadova AO. The state of oncological care for the population of Russia in 2020. Moscow; 2021. (In Russ.).

2. Nie H, Bu F, Xu J, Li T, Huang J. 29 immune-related genes pairs signature predict the prognosis of cervical cancer patients. Sci Rep. 2020; 10: 14152. doi: 10.1038/s41598-020-70500-5

3. Paik E, Lim MC, Kim MH, Kim YuH, Song ES, Seong JS, et al. Prognostic model for survival and recurrence in patients with early-stage cervical cancer: A Korean Gynecologic Oncology Group study (KGOG 1028). Cancer Res Treat. 2020; 52(1): 320-333. doi: 10.4143/crt.2019.124

4. Maksimov AY, Timoshkova MY, Verenikina EV, Lukbanova EA, Kecheryukova MM. Evaluation of microRNA profile in cervical epithelium for predicting cervical cancer recurrence. Almanac of Clinical Medicine. 2020; 48(5): 333-340. (In Russ.). doi: 10.18786/2072-0505-2020-48-054

5. Weng Sh, Wu W, Hsiao Y, Yang Sh, Hsu Ch, Wang P. Significant association of long non-coding RNAs HOTAIR genetic polymorphisms with cancer recurrence and patient survival in patients with uterine cervical cancer. Int J Med Sci. 2018; 15(12): 1312-1319. doi: 10.7150/ijms.27505

6. Fu HC, Yang YC, Chen YJ, Lin H, Ou YC, Chien CC, et al. Increased expression of SKP2 is an independent predictor of locoregional recurrence in cervical cancer via promoting DNA-damage response after irradiation. Oncotarget. 2016; 7(28): 44047-44061. doi: 10.18632/oncotarget.10057

7. Nishanov DA, Mamadaliyeva YS, Zakirova NN, Karimova NS. Prognostic role of expression of molecular genetic markers in determining survival in locally advanced cervical cancer. Onkologicheskiy zhurnal. 2020; 14(4): 79-85. (In Russ.).

8. Hu YuX, Zheng MJ, Zhang WCh, Li X, Gou R, Nie X, et al. Systematic profiling of alternative splicing signature reveals prognostic predictor for cervical cancer. J Transl Med. 2019; 17: 379. doi: 10.1186/s12967-019-02140-x

9. Yang HJ, Xue JM, Li J, Wan LH, Zhu YuX. Identification of key genes and pathways of diagnosis and prognosis in cervical cancer by bioinformatics analysis. Mol Genet Genomic Med. 2020; 8(6): e1200. doi: 10.1002/mgg3.1200

10. Ashrafyan LA, Belokrinitskaya TE, Kayukova EV, Sholokhov LF, Mudrov VA, Tereshkov PP. The local level checkpoint proteins of immune cycle in patients with cervical cancer. Transbaikalian Medical Bulletin. 2021; 4: 11-20. (In Russ.). URL: http://zabmedvestnik.ru/arhiv-nomerov/nomer-4-za-2021-god/lokalnyjuroven-belkov-kontrolnyh-tochek-immunnogo-cikla-u-bolnyhrakom-shejki-matki [date of access: 01.06.2021].

11. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication. Haematologica. 2004; 89(3): 264.

12. Mudrov VA. ROC curve analysis algorithm in biomedical research using SPSS software package. Transbaikalian Medical Bulletin. 2021; 1: 148-153. (In Russ.). URL: http://zabmedvestnik.ru/arhiv-nomerov/nomer-1-za-2021/algoritm-primenenija-rocanaliza-v-biomedicinskih-issledovanijah-s-pomoshhju-paketaprogramm-spss/975/18.pdf [date of access: 01.06.2021].

13. Nandi D, Pathak S, Verma T, Singh M, Chattopadhyay S, Thakur A, et al. T cell costimulation, checkpoint inhibitors and antitumor therapy. J Biosci. 2020; 45:50.

14. Heeren A, Punt S, Bleeker M, Gaarenstroom K, van der Velden J, Kenter G, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Modern Pathology. 2016; 29: 753-763. doi: 10.1038/modpathol.2016.64

15. Liu Y, Wu L, Tong R, Yang F, Yin L, Li M, et al. PD-1/PD-L1 inhibitors in cervical cancer. Front Pharmacol. 2019; 10: 65. doi: 10.3389/fphar.2019.00065

16. Minion L, Tewari K. Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018: 148(3): 609-621. doi: 10.1016/j.ygyno.2018.01.009

17. Rotman J, den Otter L, Bleeker M, Samuels S, Heeren A, Roemer M, et al. PD-L1 and PD-L2 expression in cervical cancer: Regulation and biomarker. Front Immunol. 2020; 11: 596825. doi: 10.3389/fimmu.2020.596825

18. O’Neill R, Cao X. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. Adv Cancer Res. 2019; 143: 145-194. doi: 10.1016/bs.acr.2019.03.003